Clinical Trial Update: Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib with or without recombinant interferon alfa-2b in patients with metastatic renal cell carcinoma; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Intron A (interferon alfa-2b)
• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-09-16